Cancer Prevalence Low in Power Morcellation Fibroid Removal

This article originally appeared here.
Share this content:
Cancer Prevalence Low in Power Morcellation Fibroid Removal
Cancer Prevalence Low in Power Morcellation Fibroid Removal

FRIDAY, Feb. 20, 2015 (HealthDay News) -- The use of power morcellation to remove fibroids in the uterus can end up spreading bits of hidden cancerous tumors throughout the abdomen, but a new study suggests the likelihood is low. Researchers called the findings, reported online Feb. 19 in JAMA Oncology, "reassuring."

The new study was done to determine how many women having fibroids removed -- but not the uterus -- might have hidden cancer, lead researcher Jason Wright, M.D., chief of gynecologic oncology at Columbia University in New York City, explained to HealthDay. His team looked at records for 41,777 U.S. women who had fibroids surgically removed between 2006 and 2012. A power morcellator was used in 3,220 cases.

Of those women who were treated with a morcellator, three were later found to have uterine cancer -- a rate of one in 1,073 patients. By comparison, the odds of uterine cancer were one in 528 among women who had fibroids removed without the device. As expected, the likelihood of a hidden cancer increased with age: Of women younger than 40 who had power morcellation, none were found to have uterine cancer; the rate increased to almost 1 percent among women in their 50s.

"Overall, the risk is low, and I think that's reassuring," Wright said. He noted that the results are also in line with the U.S. Food and Drug Administration's recommendations for older and younger women.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »